Our Science
A first-in-class approach to address acute bleeding
ClotProtect are developing a first-in-class small molecule inhibitor of plasmin with superior potency and clot protection than the current standard of care - Tranexamic Acid (TXA).
Initial preclinical results show that CP101 prevents clot breakdown with significantly greater efficacy vs TXA.
1.5M
deaths are caused by traumatic bleeding annually
Excess bleeding is the highest cause of mortality from trauma & surgery
Bleeding is responsible for about 40% of all trauma deaths worldwide. During surgery, the risks of traumatic bleeding are particularly pronounced with major blood loss associated with an 8x increase in mortality.
CP-101 offers anticipated superiority in both potency & clot protection vs. TXA
TXA, the current standard of care for patients at risk of acute bleeding suffers from limitations because it does not inhibit plasmin directly. Therefore, CP-101 will provide:
Better efficacy, reduced mortality
Less inflammation & reduced risk of multi-organ failure
Shorter hospital stays, fewer blood products & lower costs
Unique mode of action
Unlike TXA which blocks only on the tPA pathway and enhances the uPA pathway, CP101 blocks plasmin from all 3 pathways (tPA, uPA and kallikrein pathway).
It also blocks circulating plasmin, even that which is circulating prior treatment. This results in a significant reduction in plasmin generated.
*yet to be tested on man